Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …
Board of Directors - Cingulate Inc
Shane J. Schaffer, PharmD is a Co-Founder of Cingulate Therapeutics and has served as the CEO since its inception. Dr. Schaffer is a 25-year pharmaceutical industry veteran with experience in …
Dr. Alice Mao, MD - Advisors | Cingulate Inc
The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.
SEC Filings - Cingulate Inc
Dec 15, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301
Final Study Completed for Cingulate’s Lead Asset CTx-1301 - Cingulate …
Jan 7, 2025 · The subjects in the study were given a single 50mg dose of CTx-1301, Cingulate’s highest dosage, to determine if the medication can be taken in fed and fasted states. No serious adverse …
Press Releases - Cingulate Inc
Nov 10, 2025 · Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 …
0001493152-24-004061 | 8-K | iXBRL Viewer | Cingulate INC
Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).